Search

for
Search:

GlossaryStomatitis

inflammation of mouth's mucous membranes causing sores and discomfort

Stomatitis is the inflammation of the mucous membranes in the mouth, which can cause symptoms like redness, swelling, and sores. It can result from various factors, including infections, irritants, or underlying health conditions, and may affect eating, speaking, and overall oral health.

Related Terms

Research

5 / 465 results

research Potential of Natural Products in Hangeshashinto Water Extract on the Direct Suppression of Stomatitis Induced by Intra-/Extracellular Advanced Glycation End-Products

September 2025 in “International Journal of Molecular Sciences”

Hangeshashinto's natural products may help treat stomatitis by reducing inflammation and cytotoxicity.

Fatigue, Alopecia, and Stomatitis Among Patients With Breast Cancer Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Systematic Review and Meta-Analysis

research Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis

28 citations , July 2017 in “Expert Review of Anticancer Therapy”

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

research Fever, Maculopapular Rash and Severe Aphthous Stomatitis in a Renal Transplant Patient

December 2013 in “American journal of transplantation”

The patient improved after antiviral treatment for a viral infection.

Reduced Cardiotoxicity and Comparable Efficacy in a Phase III Trial of Pegylated Liposomal Doxorubicin HCl (CAELYX/Doxil) Versus Conventional Doxorubicin for First-Line Treatment of Metastatic Breast Cancer

research Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

1461 citations , March 2004 in “Annals of oncology”

Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.

research First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

505 citations , October 2011 in “Journal of clinical oncology”

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

View more "stomatitis" in research →

Learn

— no results

Try a deeper search in learn →

Community Join

— no results

Try a deeper search in community →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →